Evidence map›Paper›PMID 36735214›Full record

ReviewDermatology and therapy2023

Pimecrolimus for the Treatment of Atopic Dermatitis in Infants: An Asian Perspective.

Chia-Yu Chu, Tsung-Chieh Yao, I-Hsin Shih, Chin-Yi Yang, Chan Lee Chin, Sabeera Begum Binti Kader Ibrahim, Suganthi Thevarajah, Leong Kin Fon, Marco Hok-Kung Ho, Chow Chung Mo and 3 more

Open access · goldAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Dermatology and therapy, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed, 1 pooled it
1.1field-weighted citation impact, top 22% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 1 synthesis or guideline pooled it, 4 citations in OpenAlex.

  1. Pooled it
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 8 institutions in 5 countries.

Chia-Yu ChuDepartment of Dermatology, National Taiwan University Hospital and National Taiwan University College of Medicine, Taipei, Taiwan.
Tsung-Chieh YaoDepartment of Pediatrics, Chang Gung Memorial Hospital and Chang Gung University College of Medicine, Taoyuan, Taiwan.
I-Hsin ShihDepartment of Dermatology, Chang Gung Memorial Hospital, Linkou Branch, Taoyuan, Taiwan.
Chin-Yi YangDepartment of Dermatology, Chang Gung Memorial Hospital, Linkou Branch, Taoyuan, Taiwan.
Chan Lee ChinNorthern Skin Specialist Clinic, Penang, Malaysia.
Sabeera Begum Binti Kader IbrahimHospital Kuala Lumpur, Kuala Lumpur, Malaysia.
Suganthi ThevarajahHospital Kuala Lumpur, Kuala Lumpur, Malaysia.
Leong Kin FonPediatric Institute, Kuala Lumpur General Hospital, Kuala Lumpur, Malaysia.
Marco Hok-Kung HoThe University of Hong Kong, Pok Fu Lam, Hong Kong.
Chow Chung MoPrince of Wales Hospital, Shatin, Hong Kong.
Chow Pok YuThe University of Hong Kong, Pok Fu Lam, Hong Kong.
Steven King-Fan LooThe Hong Kong Institute of Integrative Medicine, The Chinese University of Hong Kong, Shatin, Hong Kong.
Thomas LugerDepartment of Dermatology, University of Muenster, Muenster, Germany. luger@uni-muenster.de.ORCID http://orcid.org/0000-0003-1397-1626
Hospital Kuala Lumpur · MYChang Gung Memorial Hospital · TWUniversity of Hong Kong · HKChang Gung University · TWChinese University of Hong Kong · HKNational Taiwan University Hospital · TWPrince of Wales Hospital · CNUniversity of Münster · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Atopic dermatitis (AD) is a common chronic, multisystem inflammatory skin disease in pediatric patients. There has been an increase in the incidence of AD in the pediatric population of the Asia-Pacific region. Studies have shown that genetic, epigenetic, environmental and cultural factors may lead to differences in the clinical manifestation and prevalence of AD between races. Early treatment of AD is necessary to prevent the atopic march leading to comorbidities such as asthma and allergic rhinitis. Topical corticosteroids (TCS) are used as first-line therapy for the treatment of AD, but their long-term usage poses a risk to the patient's health. Pimecrolimus (1%) is a topical calcineurin inhibitor (TCI) that is indicated for the treatment of mild to moderate AD. Pimecrolimus has no apparent increase in adverse events compared to TCS, and it causes less of a burning sensation than tacrolimus. The safety and efficacy of pimecrolimus has been established through various clinical trials; yet, in many Asian countries, the use of pimecrolimus in infants is still restricted due to safety concerns. Based on the available evidence, the expert panel recommends pimecrolimus in infants between 3 months and 2 years of age in the Asian population.

Indexed as

Asian populationAtopic dermatitisInfantsPimecrolimusTopical calcineurin inhibitor

Identifiers

PMID36735214
PMCPMC9984644
OpenAlexW4319062318

What Socratic holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.